BioNTech (NASDAQ:BNTX) Shifts Focus to Oncology, Receives Buy Rating from Goldman Sachs

Core Insights - BioNTech is shifting its focus back to oncology, leveraging its mRNA technology for cancer treatment [2][5] - Goldman Sachs upgraded BioNTech from Neutral to Buy, citing the company's potential in cancer treatment [2][5] - BioNTech has a substantial cash reserve of $17 billion to support late-stage development [2][5] Company Performance - BioNTech has delivered five billion doses of its COVID-19 vaccine globally, reaching over 180 countries [3][5] - The company is conducting 25 clinical trials with 16 clinical programs currently in progress [3][5] - Despite a recent stock price decrease of 2.80%, the current price is $106.07, with a market capitalization of approximately $25.51 billion [4]